Novel Pan-Lysyl Oxidase Inhibitor PXS-5505 for Improving Pancreatic Cancer Treatment
EACRvideos via YouTube
Power BI Fundamentals - Create visualizations and dashboards from scratch
Cybersecurity: Ethical Hacking Fundamentals - Self Paced Online
Overview
Google, IBM & Meta Certificates — All 10,000+ Courses at 40% Off
One annual plan covers every course and certificate on Coursera. 40% off for a limited time.
Get Full Access
Learn about groundbreaking pancreatic cancer research in this 21-minute scientific presentation where Dr. Jessica Chitty and Dr. Thomas Cox discuss their development and validation of PXS-5505, a novel selective and irreversible pan-lysyl oxidase inhibitor. Explore how this small molecule drug enhances chemotherapy effectiveness by targeting the tumor microenvironment, with detailed insights into the combined effects of PXS-5505 and gemcetabine on tumor morphology, behavior, and subject survival rates. Published in Nature Cancer and featured in EACR's Highlights in Cancer Research, discover the experimental results from multiple pre-clinical models that demonstrate the potential of this innovative treatment approach for pancreatic cancer patients.
Syllabus
Research focus: a novel pan-lysyl oxidase inhibitor for improving the treatment of pancreatic cancer
Taught by
EACRvideos